Last reviewed · How we verify

Suzhou Puhe Pharmaceutical Technology Co., LTD — Portfolio Competitive Intelligence Brief

Suzhou Puhe Pharmaceutical Technology Co., LTD pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pemetrexed+carboplatin/Cisplatin Pemetrexed+carboplatin/Cisplatin phase 3 Antifolate antimetabolite + platinum-based chemotherapy combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents) Oncology
YK-209A tablet YK-209A tablet phase 3 PI3K inhibitor PI3K Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
  3. Aptarion Biotech AG · 1 shared drug class
  4. Amorphical Ltd. · 1 shared drug class
  5. Angitia Incorporated Limited · 1 shared drug class
  6. Applied Biology, Inc. · 1 shared drug class
  7. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  8. Addpharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Suzhou Puhe Pharmaceutical Technology Co., LTD:

Cite this brief

Drug Landscape (2026). Suzhou Puhe Pharmaceutical Technology Co., LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzhou-puhe-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.

Related